Floatz logo

Polyiclc

Brain and Central Nervous System Tumors

University Hospital, GenevaPhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Brain and Central Nervous System Tumors cohort.

Asset / SponsorPhaseRating
Procarbazine
Universitätsmedizin Mannheim
Phase 3BBB
(+)-VINCRISTINE
Medical University of Vienna
Phase 2BBB
Irinotecan
EpicentRx, Inc.
Phase 2BBB
VINCRISTINE SULFATE
Northwestern University
Phase 3BBB
ETOPOSIDE
NewLink Genetics Corporation
Phase 3BBB

View all 50 →

Same molecule, other indications

Polyiclc is also rated in:

melanomaDormant
B
Indicative ·
63 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →